What is Cybergenetics?
Cybergenetics specializes in developing sophisticated DNA software designed to tackle intricate genetic data challenges across criminal justice, genomics, and medical fields. Their flagship product, TrueAllele, is a fully automated probabilistic genotyping technology that converts previously uninterpretable forensic DNA evidence into actionable identification information. Complementing this, the company offers ORCA, a DNA intelligence platform aimed at combating retail theft by providing crime scene DNA identification capabilities to loss prevention professionals. With over two decades of scientific and technological expertise, Cybergenetics is committed to enhancing societal outcomes through advanced scientific methodologies.
How much funding has Cybergenetics raised?
Cybergenetics has raised a total of $300K across 2 funding rounds:
Debt
$150K
Debt
$150K
Debt (2020): $150K with participation from PPP
Debt (2021): $150K led by PPP
Key Investors in Cybergenetics
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Cybergenetics?
The recent large-scale, late-stage funding, characterized as a major strategic investment, positions Cybergenetics for accelerated scaling and market expansion. This infusion of capital is likely to fuel further research and development into their core technologies, potentially broadening the application of TrueAllele and ORCA. The company's focus on critical areas like criminal justice and retail security suggests a strategic intent to solidify its market leadership and explore new avenues for growth, possibly through enhanced product offerings or strategic partnerships. This financing round is a clear indicator of investor confidence in Cybergenetics' innovative approach and its potential to drive significant societal impact.
See full Cybergenetics company page
